Literature DB >> 30229904

Ochronosis Presenting as Methemoglobinemia.

Sarah B Hugar1, Joshua Shulman2, Joseph Yanta2, Jeffrey Nine1.   

Abstract

Ochronosis is the blue-gray discoloration of collagen-containing tissues due to homogentisic acid (HGA) deposition, secondary to endogenous alkaptonuria or exogenous enzyme inhibition. In renal disease, accumulation of HGA in serum can cause methemoglobinemia. A 60-year-old woman with renal disease and anemia presented with 3 days of weakness and months of gray skin discoloration. Her hemoglobin was 8.1g/dl with 24.5% methemoglobin. Despite treatment with methylene blue, exchange transfusion, and continuous renal replacement therapy, the patient died. Autopsy revealed gray discoloration and ochronotic pigment in the ribs and cartilage. Based on these findings, the patient was diagnosed with ochronosis, suggestive of alkaptonuria, complicated by methemoglobinemia. The differential diagnosis for blue-gray skin discoloration includes argyria, methemoglobinemia, and ochronosis. This patient's clinical and autopsy findings suggested alkaptonuria complicated by methemoglobinemia due to progressive renal dysfunction. Development of methemoglobinemia in the setting of chronic skin discoloration and renal failure should prompt consideration of alkaptonuria.
© 2018 American Academy of Forensic Sciences.

Entities:  

Keywords:  alkaptonuria; autopsy; forensic science; methemoglobinemia; ochronosis; renal failure; skin discoloration

Mesh:

Substances:

Year:  2018        PMID: 30229904     DOI: 10.1111/1556-4029.13907

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  2 in total

1.  Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria - Is nitisinone the solution?

Authors:  A S Davison; E Luangrath; E Selvi; L R Ranganath
Journal:  Mol Genet Metab Rep       Date:  2020-04-16

Review 2.  Clinical and Forensic Aspects of the Different Subtypes of Argyria.

Authors:  Luís Mota; Ricardo Jorge Dinis-Oliveira
Journal:  J Clin Med       Date:  2021-05-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.